These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 32603010)
1. Belatacept, kidney transplantation and COVID-19: Successful management of the first reported case within the United Kingdom. Ahmad SH; Smith R; Camilleri B Clin Transplant; 2020 Sep; 34(9):e14026. PubMed ID: 32603010 [No Abstract] [Full Text] [Related]
2. Outcomes after Conversion to a Belatacept. Baliker M Clin J Am Soc Nephrol; 2024 May; 19(5):547. PubMed ID: 38717782 [No Abstract] [Full Text] [Related]
3. Belatacept prophylaxis against organ rejection in adult kidney-transplant recipients. Del Bello A; Marion O; Milongo D; Rostaing L; Kamar N Expert Rev Clin Pharmacol; 2016; 9(2):215-27. PubMed ID: 26691282 [TBL] [Abstract][Full Text] [Related]
4. A proposed strategy for management of immunosuppression in heart transplant patients with COVID-19. Ahluwalia M; Givertz MM; Mehra MR Clin Transplant; 2020 Nov; 34(11):e14032. PubMed ID: 32621523 [TBL] [Abstract][Full Text] [Related]
6. Late isolated ocular toxoplasmosis in a belatacept-treated kidney transplant patient. Lanfranco L; Olle Delahaye P; Dorr G; Del Bello A; Kamar N Transpl Int; 2016 Dec; 29(12):1352-1353. PubMed ID: 27614031 [No Abstract] [Full Text] [Related]
7. Attenuated early inflammatory response in solid organ recipients with COVID-19. Bösch F; Börner N; Kemmner S; Lampert C; Jacob S; Koliogiannis D; Stangl M; Michel S; Kneidinger N; Schneider C; Fischereder M; Irlbeck M; Denk G; Werner J; Angele MK; Guba MO Clin Transplant; 2020 Oct; 34(10):e14027. PubMed ID: 32589760 [TBL] [Abstract][Full Text] [Related]
9. Viral Dynamics of SARS-CoV-2 in Critically Ill Allogeneic Hematopoietic Stem Cell Transplant Recipients and Immunocompetent Patients with COVID-19. Roedl K; Heidenreich S; Pfefferle S; Jarczak D; Urbanowicz TT; Nörz D; Aepfelbacher M; Kröger N; Kluge S; Lütgehetmann M; Christopeit M; Wichmann D Am J Respir Crit Care Med; 2021 Jan; 203(2):242-245. PubMed ID: 33253054 [No Abstract] [Full Text] [Related]
10. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial. Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299 [TBL] [Abstract][Full Text] [Related]
11. Glucose Metabolism After Kidney Transplantation: Insulin Release and Sensitivity With Tacrolimus- Versus Belatacept-Based Immunosuppression. Müller MM; Schwaiger E; Kurnikowski A; Haidinger M; Ristl R; Tura A; Pacini G; Werzowa J; Hecking M Am J Kidney Dis; 2021 Mar; 77(3):462-464. PubMed ID: 32905816 [No Abstract] [Full Text] [Related]
12. The National Guard Health Affairs guidelines for the medical management of renal transplant patients. Arabi Z; Theaby A; Farooqui M; Abdalla M; Hajeer A; Abdullah K Saudi J Kidney Dis Transpl; 2018; 29(6):1452-1469. PubMed ID: 30588979 [No Abstract] [Full Text] [Related]
13. Belatacept Rescue Therapy in the Early Period After Simultaneous Kidney-Pancreas Transplantation. Esposito L; Cuellar E; Marion O; Del Bello A; Hebral AL; Sallusto F; Muscari F; Prudhomme T; Kamar N Transpl Int; 2024; 37():12628. PubMed ID: 38665473 [No Abstract] [Full Text] [Related]
14. Recurrent Psoriasis After Introduction of Belatacept in 2 Kidney Transplant Recipients. Cicora F; Roberti J Prog Transplant; 2016 Jun; 26(2):109-11. PubMed ID: 27207397 [TBL] [Abstract][Full Text] [Related]
15. Plasmapheresis Decreases Belatacept Exposure: Requires Consideration for Dose and Frequency Adjustments. Jain A; Xu R; Venkataramanan R; Farooq U; Butt F; Ghahramani N; Kadry Z Transplantation; 2021 Oct; 105(10):e152-e153. PubMed ID: 34591818 [No Abstract] [Full Text] [Related]
16. Effect of Calcineurin Inhibitors and Mammalian Target of Rapamycin Inhibitors on the Course of COVID-19 in Kidney Transplant Recipients. Hasbal NB; Turgut D; Gok Oguz E; Ulu S; Gungor O Ann Transplant; 2021 Mar; 26():e929279. PubMed ID: 33707409 [TBL] [Abstract][Full Text] [Related]
17. An update on chemical pharmacotherapy options for the prevention of kidney transplant rejection with a focus on costimulation blockade. Kälble F; Schaier M; Schäfer S; Süsal C; Zeier M; Sommerer C; Morath C Expert Opin Pharmacother; 2017 Jun; 18(8):799-807. PubMed ID: 28460546 [TBL] [Abstract][Full Text] [Related]
18. Belatacept and Autoimmune Adverse Events. Ville S; Cantarovich D Transplantation; 2018 Jul; 102(7):e355-e356. PubMed ID: 29672443 [No Abstract] [Full Text] [Related]
19. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients. Sethi S; Najjar R; Peng A; Choi J; Lim K; Vo A; Jordan SC; Huang E Transplantation; 2020 Jul; 104(7):1500-1507. PubMed ID: 31568398 [TBL] [Abstract][Full Text] [Related]
20. Coronavirus disease 2019 in renal transplant recipients: Report of two cases. Cheng D; Wen J; Liu Z; Lv T; Chen JS Transpl Infect Dis; 2020 Oct; 22(5):e13329. PubMed ID: 32415905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]